Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study.
Digoxin treatment is associated with an increased incidence of breast cancer: a population-based case-control study.
复制标题
DOI：
10.1186/bcr2205
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Pedersen L
中科院分区：
文献类型：
--
作者：
Ahern TP;Lash TL;Sørensen HT;Pedersen L
实验室和流行病学研究表明，强心苷（如地高辛和洋地黄毒苷）对癌症风险具有调节作用。我们探讨了地高辛治疗与丹麦绝经后妇女浸润性乳腺癌发病率之间的关系。我们使用丹麦登记处，以确定1991年1月1日至2007年12月31日期间诊断为偶发浸润性乳腺癌的5,565名绝经后妇女，以及55,650名匹配的人群对照。强心苷处方从县处方登记处确定。所有受试者均记录了至少2年的处方药和病史数据。我们在条件logistic回归模型中估计了地高辛使用与乳腺癌相关的比值比，该模型调整了年龄、居住县、抗凝剂、非甾体抗炎药（NSAID）、阿司匹林和激素替代治疗的使用。我们还探讨了适应症和检测偏倚混杂的影响。地高辛是研究期间处方给受试者的唯一强心苷。有324例乳腺癌病例（5.8%）和2,546例对照（4.6%）在索引日期前至少1年有地高辛使用史（调整后的比值比（OR）：1.30; 95%置信区间：1.14至1.48）。随着地高辛暴露持续时间的增加，乳腺癌OR适度增加（地高辛用途：使用7 - 18年的校正OR：1.39; 95%置信区间：1.10 - 1.74）。经年龄、接受激素替代治疗、共处方药物和适应症混杂因素校正后，该相关性稳健。病例组和对照组之间筛查性乳腺X线摄影率的比较没有发现检测偏倚的证据。我们的研究结果表明，地高辛治疗增加了绝经后妇女患浸润性乳腺癌的风险。
Laboratory and epidemiologic studies have suggested a modifying effect of cardiac glycosides (for example, digoxin and digitoxin) on cancer risk. We explored the association between digoxin treatment and invasive breast cancer incidence among postmenopausal Danish women. We used Danish registries to identify 5,565 postmenopausal women diagnosed with incident invasive breast carcinoma between 1 January 1991 and 31 December 2007, and 55,650 matched population controls. Cardiac glycoside prescriptions were ascertained from county prescription registries. All subjects had at least 2 years of recorded prescription drug and medical history data. We estimated the odds ratio associating digoxin use with breast cancer in conditional logistic regression models adjusted for age, county of residence, and use of anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and hormone replacement therapy. We also explored the impact of confounding by indication and detection bias. Digoxin was the sole cardiac glycoside prescribed to subjects during the study period. There were 324 breast cancer cases (5.8%) and 2,546 controls (4.6%) with a history of digoxin use at least 1 year before their index date (adjusted odds ratio (OR): 1.30; 95% confidence interval: 1.14 to 1.48). The breast cancer OR increased modestly with increasing duration of digoxin exposure (adjusted OR for 7 to 18 years of digoxin use: 1.39; 95% confidence interval: 1.10 to 1.74). The association was robust to adjustment for age, receipt of hormone replacement therapy, coprescribed drugs, and confounding by indication. A comparison of screening mammography rates between cases and controls showed no evidence of detection bias. Our results suggest that digoxin treatment increases the risk of invasive breast cancer among postmenopausal women.
登录
查看更多内容
影响因子：
3.1
作者：
Ewertz, M;Holmberg, L;Kristensen, A
通讯作者：
Kristensen, A
DOI：
10.1111/j.1749-6632.2003.tb07233.x
发表时间：
2003-01-01
期刊：
NA,K-ATPASE AND RELATED CATION PUMPS
影响因子：
--
作者：
Aizman, O;Aperia, A
通讯作者：
Aperia, A
影响因子：
3.8
作者：
Haux J;Klepp O;Spigset O;Tretli S
通讯作者：
Tretli S
影响因子：
105.7
作者：
Sorensen, Henrik Toft;Christensen, Steffen;Baron, John A.
通讯作者：
Baron, John A.
影响因子：
3.4
作者：
McGettigan, Patricia;Han, Pearline;Henry, David
通讯作者：
Henry, David